Effects of supplement McB on cognitive function in Patients with Mild Cognitive Impairment and mild dementia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071200050

Enrollment

Registered

2020-11-13

Start date

2021-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Cognitive Impermeant :MCI and Mild Dementia includes Alzheimer's dementia Mild Cognitive Impermeant

Interventions

arm of Active:Capsule includes Momordica Charantia Fruit Extract (7.5mg/Cap) given on twice daily for 12 weeks followed,and optional continuation is until 24 weeks arm of Placebo:Capsule without Momor

assignment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Persons with an MMSE scorefrom 21 to 27, who agreed with the purpose of this research

Exclusion criteria

Exclusion criteria: persons with serious illnesses such as malignant tumors and cerebrovascular disorders, and other mental disorders

Design outcomes

Primary

Measure	Time frame
Comparative study of MMSE, RBANS and CGI score changes	—

Secondary

Measure	Time frame
Comparative study of changes in NPI, GDS15, actigraph, cerebral blood flow SPECT test	—

Contacts

Public ContactYoshihisa Shoji

Kurume University Hospital

yshoji@med.kurume-u.ac.jp+81-942-31-7613

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026